S. R. Seshasai, S. Kaptoge, A. Thompson, D. Angelantonio, E. Gao et al., Diabetes mellitus, fasting glucose, and risk of cause-specific death, N Engl J Med, vol.364, pp.829-841, 2011.

M. F. Piepoli, A. W. Hoes, S. Agewall, C. Albus, C. Brotons et al., European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts), 2016.

, Eur Heart J, vol.37, pp.2315-2381, 2016.

K. Galougahi, K. Antoniades, C. Nicholls, S. J. Channon, K. M. Figtree et al., Redox biomarkers in cardiovascular medicine, Eur Heart J, vol.36, p.1582, 2015.

M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, Nature, vol.414, pp.813-820, 2001.

M. C. Meuwese, E. S. Stroes, S. L. Hazen, J. N. Van-miert, J. A. Kuivenhoven et al., Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study, J Am Coll Cardiol, vol.50, pp.159-165, 2007.

P. Holvoet, Oxidized LDL and coronary heart disease, Acta Cardiol, vol.59, pp.479-484, 2004.

M. C. Thomas, M. Woodward, B. Neal, Q. Li, R. Pickering et al., Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes, Diabetes Care, vol.38, pp.1891-1897, 2015.

Z. K. Yang, Y. Shen, W. F. Shen, L. J. Pu, H. Meng et al., Elevated glycated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease, Int J Cardiol, vol.197, pp.241-247, 2015.

H. Yucel, K. A. Turkdogan, A. Zorlu, H. Aydin, R. Kurt et al., Association between oxidative stress index and post-CPR early mortality in cardiac arrest patients: a prospective observational study, Anatol J Cardiol, vol.15, pp.737-743, 2015.

S. Charpentier, J. L. Ducasse, M. Cournot, F. Maupas-schwalm, M. Elbaz et al., Clinical assessment of ischemia-modified albumin and heart fatty acid-binding protein in the early diagnosis of non-ST-elevation acute coronary syndrome in the emergency department, Acad Emerg Med, vol.17, pp.27-35, 2010.

P. H. Manso, F. Carmona, F. Dal-pizzol, F. Petronilho, F. Cardoso et al., Oxidative stress markers are not associated with outcomes after pediatric heart surgery, Paediatr Anaesth, vol.23, pp.188-194, 2013.

S. Radovanovic, A. Savic-radojevic, M. Pljesa-ercegovac, T. Djukic, S. Suvakov et al., Markers of oxidative damage and antioxidant enzyme activities as predictors of morbidity and mortality in patients with chronic heart failure, J Card Fail, vol.18, pp.493-501, 2012.

A. Wykretowicz, K. Adamska, T. Krauze, P. Guzik, A. Szczepanik et al., The plasma concentration of advanced oxidation protein products and arterial stiffness in apparently healthy adults, Free Radic Res, vol.41, pp.645-649, 2007.

Y. Y. Chiu-braga, S. Y. Hayashi, M. Schafranski, . Messias-reason, and . Ij, Further evidence of inflammation in chronic rheumatic valve disease (CRVD): high levels of advanced oxidation protein products (AOPP) and high sensitive C-reactive protein (hs-CRP), Int J Cardiol, vol.109, pp.275-276, 2006.

E. Ho, K. Galougahi, K. Liu, C. C. Bhindi, R. Figtree et al., Biological markers of oxidative stress: applications to cardiovascular research and practice, Redox Biol, vol.1, pp.483-491, 2013.

M. A. Prieto and J. A. Vazquez, A time-dose model to quantify the antioxidant responses of the oxidative hemolysis inhibition assay (OxHLIA) and its extension to evaluate other hemolytic effectors, Biomed Res Int, p.632971, 2014.

S. Hadjadj, F. Fumeron, R. Roussel, P. J. Saulnier, Y. Gallois et al., Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR), diabete de type 2, nephropathie et genetique (DIAB2NEPHRO-GENE), and survie, diabete de type 2 et genetique (SURDIAGENE) studies, SURDIAGENE Study Group, vol.31, pp.1847-1852, 2008.

P. J. Saulnier, E. Gand, S. Ragot, G. Ducrocq, J. M. Halimi et al.,

. Surdiagene-study-group, Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE cohort, Diabetes Care, vol.37, pp.1425-1431, 2014.

P. Sosner, C. Hulin-delmotte, P. J. Saulnier, S. Cabasson, E. Gand et al., Cardiovascular prognosis in patients with type 2 diabetes: contribution of heart and kidney subclinical damage, Am Heart J, vol.169, pp.108-114, 2015.

S. Delbosc, D. Diallo, T. Dejouvencel, Z. Lamiral, L. Louedec et al., Impaired high-density lipoprotein anti-oxidant capacity in human abdominal aortic aneurysm, Cardiovasc Res, vol.100, pp.307-315, 2013.

H. Range, J. Labreuche, L. Louedec, P. Rondeau, C. Planesse et al., Periodontal bacteria in human carotid atherothrombosis as a potential trigger for neutrophil activation, Atherosclerosis, vol.236, pp.448-455, 2014.

J. P. Fine and R. J. Gray, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999.

O. V. Demler, M. J. Pencina, and D. Sr, Misuse of DeLong test to compare AUCs for nested models, Stat Med, vol.31, pp.2577-2587, 2012.

M. J. Pencina, D. Sr, D. Jr, and R. S. Vasan, Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond, Stat Med, vol.27, pp.207-112, 2008.

S. Masi, D. 'aiuto, F. Cooper, J. Salpea, K. Stephens et al., Telomere length, antioxidant status and incidence of ischaemic heart disease in type 2 diabetes, Int J Cardiol, vol.216, pp.159-164, 2016.

S. Koestenbauer, P. Stiegler, V. Stadlbauer, U. Mayrhauser, B. Leber et al., Myeloperoxidase and carbonyl proteins: promising markers for non-invasive monitoring of graft rejection after heart transplantation, J Heart Lung Transplant, vol.29, pp.1352-1357, 2010.

L. Lu, L. J. Pu, Q. Zhang, L. J. Wang, S. Kang et al., Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes, Atherosclerosis, vol.206, pp.540-545, 2009.

C. Spadaccio, G. Patti, D. Marco, F. Coccia, R. et al., Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study), Am J Cardiol, vol.112, pp.21-26, 2013.

M. Lazo, M. K. Halushka, L. Shen, N. Maruthur, C. M. Rebholz et al., Soluble receptor for advanced glycation end products and the risk for incident heart failure: the Atherosclerosis Risk in Communities Study, Am Heart J, vol.170, pp.961-967, 2015.

V. L. Bodiga, S. R. Eda, and S. Bodiga, Advanced glycation end products: role in pathology of diabetic cardiomyopathy, Heart Fail Rev, vol.19, pp.49-63, 2014.

G. Munch, R. Keis, A. Wessels, P. Riederer, U. Bahner et al., Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA, Eur J Clin Chem Clin Biochem, vol.35, pp.669-677, 1997.

K. Kiuchi, J. Nejima, T. Takano, M. Ohta, and H. Hashimoto, Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients, Heart, vol.85, pp.87-91, 2001.

Y. Aso, T. Inukai, K. Tayama, and Y. Takemura, Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes, Acta Diabetol, vol.37, pp.87-92, 2000.

B. K. Kilhovd, A. Juutilainen, S. Lehto, T. Ronnemaa, P. A. Torjesen et al., High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study, Arterioscler Thromb Vasc Biol, vol.25, pp.815-820, 2005.

N. M. Hanssen, J. W. Beulens, S. Van-dieren, J. L. Scheijen, A. Van-der et al., Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL), Diabetes, vol.64, pp.257-265, 2015.

N. A. Roper, R. W. Bilous, W. F. Kelly, N. C. Unwin, and V. M. Connolly, South Tees Diabetes Mortality Study. Cause-specific mortality in a population with diabetes: South Tees Diabetes Mortality Study, Diabetes Care, vol.25, pp.43-48, 2002.